BTK and B-cell chronic lymphocytic leukemia: Abundant expression of BTK has been identified in B-cell chronic lymphocytic leukaemia (CLL) and B-cell lymphomas, making it a promising target for the development of new small-molecule inhibitors [5,6,7].